PR-171

An epoxomicin derivate with potential antineoplastic activity. PR-171 irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2016
012320072016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given orally twice… (More)
  • table I
  • table II
  • table III
  • table V
Is this relevant?
2011
2011
Carfilzomib [(2S)-N-[(S)-1-[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxopentan-2-ylcarbamoyl]-2-phenylethyl]-2-[(S)-2-(2… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2011
2011
Carfilzomib (formerly PR-171) is a novel epoxyketone-based irreversible proteasome inhibitor. In preclinical studies, carfilzomib… (More)
Is this relevant?
2010
2010
Proteasomes degrade most proteins in mammalian cells and are established targets of anti-cancer drugs. The majority of proteasome… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and structurally… (More)
Is this relevant?
2009
2009
Purpose: Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2009
Review
2009
New chemotherapeutic agents are still required to further optimise treatment of leukemia patients. Proteasome inhibition by… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Proteasome inhibitors represent a new class of antineoplastic drugs that are considered in the treatment of haematological… (More)
Is this relevant?